



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 21st APRIL 2021

PRESENT:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr T McKenzie (TM)	GP East Lancs
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Ms F Iqbal	Senior Pharmacist NHS BwD CCG
Mrs C Harding	Senior Pharmacist, LCFT

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
-------------	---

2021/054: APOLOGIES:

Mr U Akram (UA)	Pharmacist, Lancashire Care Foundation Trust
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT

2021/055: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2021/056: MINUTES OF MARCH Teams MEETING:

Spelling error item 2021/025 acknowledged – Circaidin® should read Circardin®

2021/057: MATTERS ARISING:

2021/044: Dapagliflozin (TA679) – item closed. Information received

DHSS Vitamin D in Care Homes

Medicines Management circulated a Hot Topic in relation to the Government decision to arrange delivery of Vitamin D supplements to Care Home residents during Covid-19. However, another further document has been circulated directly without coming to ELMMB for clinical discussion. The paper 'medicalises' the use of Vitamin D, rather than identifying them as a food supplement. This has generated many queries for GP practices and the MM Care Home Team. CQC have confirmed that the use of vitamin D is as a food supplement and the use should be documented in the patients care plan and not added to the MAR chart. VG to flag issue on cell call later today and ask that any clinical/medicinal documents need to come through ELMMB for governance purposes before distribution.

ACTION: VG to update at next meeting

National Protocol updates for Covid Vaccines

- COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)
- COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [recombinant])
- COVID-19 Vaccine Moderna

Latest national protocols acknowledged by ELMMB

2021/058: LSCMMG CONSULTATIONS (FOR MAY LSCMMG)

Actectura Breezhaler – New Medicine Assessment

Energair Breezhaler – New Medicines Assessment

For both the above assessments it was agreed that the choices available be streamlined when review takes place. Trimbow® as triple therapy in asthma also to be considered as part of the review.

Primary Care Management of Erectile Dysfunction – request that the line 'patients should have a cardio-vascular risk assessment' be added to the first page.

Ketamine for non-cancer chronic pain – Consultation 3 – supported as BLACK traffic light

Comments to be sent to LSCMMG

2021/059: LSCMMG Recommendations (from March LSCMMG)

Linezolid Information sheet – accepted for use by ELMMB once approval received from microbiology

Position Statement - Private GIC prescribing requests Concerns raised of safety aspects when requested to prescribe these very high-risk drugs for an unlicensed use. There is no supporting NICE guidance and often GPs are under pressure to prescribe. Numbers of patients are also rising. ELMMB acknowledge the statement but the concerns raised at practice level will be taken to next LSCMMG to discuss further options regarding supply of the medicines such as Homecare arrangements, and support to GP practices.

Gender dysphoria information sheets – updated Acknowledged by ELMMB

2021/060: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS

Domperidone - As a galactagogue for birth mothers and mothers of adopted babies
– acknowledged by ELMMB

Semaglutide Tablets - for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise
– acknowledged by ELMMB. Add to local formulary with comment regarding 3rd line option.

2021/061: FORMULARY UPDATES

ELHT Paediatric PPI Guideline – update to document to include esomeprazole granules in the pathway.

ACTION: pathway to be updated further for formatting and brought to next meeting

Trimbow request for Asthma indication – to be sent to LSCMMG for consideration for pathway.

ACTION: VG to feedback to Dr Hafeez and request he is involved in the meetings

ELHT Switch to dalteparin [from enoxaparin] – updated Best Practice document to be circulated before the switch to dalteparin begins in next 2 -3 weeks. There will be no traffic light changes.

Document acknowledged by ELMMB

2021/062: NICE RECOMMENDATIONS (from March)

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

NHS England Commissioned

Traffic Light: RED

Baricitinib for treating moderate to severe atopic dermatitis (TA681)

CCG Commissioned – Blueteq form required

Traffic Light: RED

Erenumab for preventing migraine (TA682)

CCG Commissioned – Blueteq form required

Traffic Light: RED

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)

Cancer Drugs Fund

Traffic Light: RED

Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)

Cancer Drugs Fund

Traffic Light: RED

Anakinra for treating Still's disease (TA685)

NHS England Commissioned

Traffic Light: RED

Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA686)

Traffic Light: BLACK

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)

Cancer Drugs Fund

Traffic Light: RED

Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
**NHSe commissioned n.b. this is a medical device and not currently commissioned
via ELHT Radiology** **Traffic Light: RED**

STANDING ITEMS

2021/063: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – March 2021

Minutes acknowledged

2021/064: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – March 2021

Minutes acknowledged

EXTRA ITEMS:

Gluten Free Position Statement

The position statement needs updating and retaining. ELHE still do not commission
Gluten Free products. Accepted and acknowledged by ELMMB

Chloramphenicol eye drops SPC change

SPC now contra indicates the use of chloramphenicol eye drops in children under the
age of 2 years due to the product containing boric acid. MHRA are currently updating
guidance.

**DATE OF NEXT MEETING – Wednesday 19th May 2021 12.30pm via ‘Microsoft
Teams’**

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 21st APRIL 2021

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed.	LR/JV	Sept 21
2020/092	Drug Safety Update – Denosumab Directorate pharmacist to discuss with consultants.	AG/VG	May 21
2021/044	NICE Recommendations (from February) – Filgotinib (TA676) – implications to be scoped with rheumatology team & estimate of numbers to CCG	VG	May 21
2021/057	Clinical/medicinal documents: Raise governance issues at regional level of necessity that they need to come to ELMMB before distribution.	VG	May 21
2021/061	ELHT Paediatric PPI Guideline: pathway to be updated	VG	May 21
2021/061	Trimbow request for Asthma indication –Dr Hafeez to be informed of decision to refer to LSCMMG for consideration for inclusion in pathway.	VG	May 21